Fig. 1
BrQ administration attenuates clinical symptoms of EAE mice. A Chemical structure of BrQ. B Schematic diagram of MOG35 − 55-induced EAE model and BrQ treatment. C Clinical scores of EAE mice treated with vehicle (0.5% CMC) or different dosages of BrQ (3, 10, or 30 mg/kg body weight) daily by gavage starting from day 3 after immunization, n = 5–6 mice per group. D The stacked column depicts EAE clinical incidence and severity from day 9 to day 21. E, G H&E staining and LFB staining of paraffin-embedded sections of spinal cords isolated from vehicle- or BrQ-treated EAE mice on day 18 post-immunization. Scale bars: 400 μm. F, H Statistical analysis of CNS inflammatory cell infiltration in H&E-stained sections and demyelination areas in luxol fast blue-stained spinal cord sections by Image-Pro software. n = 5 mice per group. I-K The disease scores of EAE mice treated with vehicle or BrQ (30 mg/kg) daily by gavage starting from day 7, day 14, or day 21 after immunization. n = 5–6 mice per group **p < 0.01, ****p < 0.0001 by two-way ANOVA. The experiments were repeated twice with consistent results